Hasn't faired well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Shares of Natco Pharma gained over 3% in a weak market today after the company received a favourable judgement from Delhi High Court in a patent infringement case of Chlorantraniliprole (CTPR) process. Natco Pharma stock rose 3.51% to Rs 599.05 today against the previous close of Rs 578.75 on BSE.

Natco Pharma stock rises 3% on favourable verdict in patent infringement case

Natco Pharma advanced 1.94% to Rs 590 after the company received a favourable judgement from Delhi High Court in a patent infringement case of Chlorantraniliprole (CTPR) process.

Natco Pharma gains on favourable verdict in CTPR patent infringement case

Key Stocks in Focus Today: HDFC, Tata Motors, Bajaj Consumer, Natco Pharma & More

Stocks to watch before going into trade today

Stocks To Watch: Adani Enterprises, Bajaj Consumer Care, Vedanta, Karur Vysya Bank, Natco Pharma

In a setback to FMC Corporation, the Delhi High Court on Monday upheld its single judge’s order that allowed Natco Pharma to roll out an insecticide Chlorantraniliprole (CTPR), saying it does not infringe the US agrochemical company’s patent.

HC upholds order allowing Natco Pharma to roll out insecticide CTPR

In May this year, Natco had announced that the corporation had filed a patent suit against it in the Delhi High Court.

Natco Pharma Receives Favourable Verdict In Patent Infringement Case

Natco Pharma receives favourable judgement in patent case

Broker’ Call: Natco Pharma (Buy)

Geojit is bullish on Natco Pharma has recommended buy rating on the stock with a target price of Rs 704 in its research report dated December 05, 2022.

Buy Natco Pharma; target of Rs 704: Geojit

The company is planning to complete an acquisition in the next few months

Natco Pharma mulling multiple acquisitions to boost domestic business

The suit is related to the proposed generic equivalents to Imbruvica tablets

Ibrutinib case: US court denies Natco Pharma’s partner Alvogen’s appeal

Natco Pharma Limited is a research and development (R&D)-focused pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).

Natco Pharma Ltd